With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai’s Alpha Bio zooms into a PhII study

One of the more prominent Chinese venture firms in biotech has put some cash behind yet another Chinese start-up looking to develop a Big Pharma drug for the booming Asian market.